Publikationen von Tilia Marlene Zinnecker
Alle Typen
Zeitschriftenartikel (2)
1.
Zeitschriftenartikel
24 (4), 2300245 (2024)
From single‐cell cloning to high‐yield influenza virus production – implementing advanced technologies in vaccine process development. Engineering in Life Sciences 2.
Zeitschriftenartikel
20 (1), 2373521 (2024)
Innovations in cell culture-based influenza vaccine manufacturing – from static cultures to high cell density cultivations. Human Vaccines & Immunotherapeutics Meeting Abstract (1)
3.
Meeting Abstract
Automated single-cell cloning in chemically defined medium for new suspension MDCK cell lines and scale-down of influenza A virus production into ambr®15 microbioreactors. In Proceedings Vaccine Technology VIII, 55. Vaccine Technology VIII, Sitges (Spain), 12. Juni 2022 - 17. Juni 2022. (2022)
Vortrag (8)
4.
Vortrag
Next-generation virus production: from clone, to AMBR, to perfusion and very high virus yield. 8th Edition of the "International Symposium on Immunobiologicals" (8th ISI), Rio de Janeiro (Brazil) (2024)
5.
Vortrag
Influenza A Virus Production following Quality by Design Principles. Vaccine Technology IX, Los Cabos (Mexico) (2024)
6.
Vortrag
Intensified cell-based virus production: A process development challenge for multiple cell-virus combinations. 16th PEACe Conference, Sitges (Spain) (2023)
7.
Vortrag
Next-Generation Virus Production: From Clone, to AMBR, to Perfusion and Very High Virus Yield. International Society for Vaccines (ISV) Annual Congress, Lausanne (Switzerland) (2023)
8.
Vortrag
Increase in supply through use of new technologies for high yield vaccines. Flanders Vaccine, Brussels (Belgium) (2023)
9.
Vortrag
Novel approach towards vaccine manufacturing: from single-cell cloning to high-yielding influenza virus production. 4th Global Bioprocessing, Bioanalytics and ATMP Manufacturing Congress, Dublin (Ireland) (2023)
10.
Vortrag
A quest for the best influenza producing clonal MDCK cell line: intensifying by design of experiments, ambr15 and bench-top bioreactor cultivations. World Biopharm Forum 2023 - Democratisation of biotherapies: new manufacturing modalities and intensifications, Oxford (United Kingdom) (2023)
11.
Vortrag
Automated single-cell cloning in chemically defined medium for new suspension MDCK cell lines and scale-down of influenza A virus production into ambr®15 microbioreactors. Vaccine Technology VIII, Sitges (Spain) (2022)
Poster (5)
12.
Poster
Influenza A Virus Production following Quality by Design Principles. Vaccine Technology IX, Los Cabos (Mexico) (2024)
13.
Poster
Implementation of Quality by Design Principles for Influenza A Virus Production. 28th ESACT Meeting, Edingburgh (Scotland) (2024)
14.
Poster
Generation and screening of monoclonal suspension MDCK cells for high-yield influenza A virus production. 3rd ESACT Frontiers Retreat, Vienna, Austria (2022)
15.
Poster
Automated single-cell cloning in chemically defined medium for new suspension MDCK cell lines and scale-down of influenza A virus production into ambr®15 microbioreactors. Vaccine Technology VIII, Sitges (Spain) (2022)
16.
Poster
Suspension MDCK cell line development by automated single-cell cloning & scale-down into ambr®15 microbioreactors in chemically defined medium. 27th ESACT Meeting, Lisbon (Portugal) (2022)
Hochschulschrift - Master (1)
17.
Hochschulschrift - Master
Single-Cell Analysis of Influenza A Virus Defective Interfering Particle Infection. Master, Technische Universität, Berlin (2021)